Clinical trial
A Phase 1 Study in Patients With Hematological Malignancies to Evaluate Safety, Tolerability and Efficacy of Karonudib
NCT04077307 is registered in ClinicalTrials.gov with Thomas Helleday Foundation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study in Patients With Hematological Malignancies to Evaluate Safety, Tolerability and Efficacy of Karonudib
- Lead sponsor
- Thomas Helleday Foundation
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- December 3, 2019
- Completion date
- April 30, 2027
- Enrollment
- 50 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.